ASTRAZENECA DL-,25 SP.ADR
[WKN: 886715 | ISIN: US0463531089]
Aktienkurse
61,250€ 0,82%
Echtzeit-Aktienkurs ASTRAZENECA DL-,25 SP.ADR
Bid: Ask:
Reuters Kategorien
dpa-AFX Compact / dpa-AFX PRO Kategorien
Traderfox: dpa-AFX ProFeed Kategorien
dpa-AFX ProFeed Kategorien

AstraZeneca: Rating gesenkt

Frankfurt (www.aktiencheck.de) - Rating-Update: Die Analysten von ODDO BHF stufen die Aktie von AstraZeneca plc (ISIN: GB0009895292, WKN: 886455, Ticker-Symbol: ZEG,…

AstraZeneca to acquire Amolyt

14 March, 2024 AstraZeneca to acquire Amolyt Pharma, expanding late-stage rare disease pipeline Amolyt development portfolio includes Phase III asset with potential to address…

EMA validates Dato-DXd MAAs for NSQ NSCLC and BC

4 March 2024 Two datopotamab deruxtecan applications validated in the EU for patients with advanced nonsquamous non-small cell lung cancer or HR-positive, HER2-negative…

Total Voting Rights

1 March 2024 15:00 GMT Transparency Directive Voting rights and capital The following notification is made in accordance with the UK Financial Conduct…

Aradhana Sarin

Aradhana Sarin led deals to expand AstraZenecas drug pipeline, and transformed the finance function to improve employee retention and productivity.…

Acquisition of Gracell completed

22 February 2024 Acquisition of Gracell completed AstraZeneca today announced the successful completion of the acquisition (https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-to-acquire-gracell-furthering-cell-therapy-ambition-across-oncology-and-autoimmune-diseases.html) of Gracell Biotechnologies Inc. (Gracell, NASDAQ: GRCL), a…

Director/PDMR Shareholding

22 February 2024 11:00 GMT Transaction by Person Discharging Managerial Responsibilities AstraZeneca PLC (the Company) announced that, on 20 February 2024, an…

AstraZeneca prices a $5bn bond offering

22 February 2024 07:00 GMT AstraZeneca prices a $5bn bond offering AstraZeneca PLC ("AstraZeneca") announces that its wholly owned subsidiary AstraZeneca Finance LLC, priced…

Filing of Form 20-F with SEC

21 February 2024 07:00 GMT Filing of Annual Report on Form 20-F with the US Securities and Exchange Commission AstraZeneca PLC (the Company) announced…

AstraZeneca completes acquisition of Icosavax

19 February 2024 Acquisition of Icosavax Completed AstraZeneca announced today the successful completion of the acquisition of Icosavax, Inc., a US-based clinical-stage…

UBS stuft ASTRAZENECA auf Sell

ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat Astrazeneca auf "Sell" mit einem Kursziel von 9900 Pence belassen. Die…

FTSE 100 LIVE: Index approaches six-month high

FTSE 100 up 21 points at 7,732. Currys in centre of bidding war. AstraZeneca, Rolls-Royce surge. 3.30pm: YouGov chief departs in key election year YouGov...…

FDA accepts Dato-DXd BLA for nonsquamous NSCLC

19 February 2024 Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell…

Tagrisso improved PFS in Stage III lung cancer

19 February 2024 Tagrisso demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial First…

AstraZeneca: Kurszielsenkung

Toronto (www.aktiencheck.de) - Rating-Update: BMO Capital Markets stuft die Aktie von AstraZeneca plc (ISIN: GB0009895292, WKN: 886455, Ticker-Symbol: ZEG, London Stock…

AstraZeneca unter der Lupe

Anzeige / WerbungAstraZeneca unter der LupeAstraZeneca ist einer der größten Arzneimittelhersteller weltweit. Ein international renommierter Pharmakonzern, der in 1999 aus…